ELCC 2025 at a glance
Looking toward ELCC 2025, LucidQuest highlights priority developments in NSCLC, SCLC, targeted therapy, immunotherapy, diagnostics, and AI/ML.
📅 Build your schedule around the topics that interest you.
📥 Download the ELCC 2025_Preview_by_LucidQuest
Dive deeper
Key Topics From ELCC Scientific Presentations
Targeted Therapy
-
Combining precision medicine with ADCs and immunotherapy is reshaping #NSCLC care.
-
EGFR and ALK inhibitors continue evolving. 🏹🩺
Chemotherapy / Combination Therapy
-
Subcutaneous vs IV pembrolizumab (MK-3475A-D77) show similar efficacy, offering patient-friendly options.
-
Metformin + FMD show potential benefits in LKB1-inactive NSCLC. 🌐💉
Biomarkers / Diagnostics
-
Liquid biopsies, NLP-driven analysis, and a new blood test with 93.1% sensitivity are boosting early detection.
-
IASLC survey highlights Europe’s better biomarker testing, but cost/time remain barriers. 🔬⚙️
Early-Stage / Resectable NSCLC
-
Neoadjuvant lazertinib for EGFR+ lung cancer.
-
Perioperative immunotherapy for KRAS mutants.
-
Comparing neoadjuvant chemo vs immunotherapy. 🙌✨
Immunotherapy
-
Studies refine chemo + immunotherapy combos for metastatic NSCLC.
-
Brain metastases data show improved survival with immunotherapy. 🍀⚕️
Radiotherapy
-
Hypofractionated RT and consolidative SRT yield better outcomes in certain stages.
-
SABR’s cardiac dose impact (LUNG HEART) underscores personalized treatment. 🏹🔎
Real-World / Observational
-
Anlotinib helps ICI-resistant NSCLC (PFS ~8.8 months).
-
PD-1 inhibitors show similar efficacy and safety.
-
Finland’s EGFR mutation incidence at 8%; median survival 23 months. 🌱📊
SCLC
-
Durvalumab consolidation curbs extrathoracic metastases.
-
Serplulimab + chemo improves outcomes in ES-SCLC (ASTROM-005R).
-
Brain metastasis benefits from first-line durvalumab. 🎯🧠
Artificial Intelligence and Machine Learning at ELCC 2025
AI in Screening
-
Tools like LungSIGHT boost sensitivity/specificity in high-risk groups, enabling earlier detection. 🤖🔎
AI in Predictive Modeling
-
ML identifies key prognostic factors for long-term survival, helping tailor therapies. 📈⚕️
Adenox and Molecular Targets
-
Models predict EGFR, KRAS, PD-L1, ensuring timely personalized treatments. 🌐🎯
AI in Radiomics and Imaging
-
Integrating clinical/lab data for higher AUC and better diagnosis odds—ideal for early detection. 🏹✨
AI in Brain Mets
-
AI evaluating survival in NSCLC with brain metastases assists local therapy decisions. 🧠💻
AI and Cost-Effectiveness
-
AI-based screening (qXR) proves cost-neutral within years, detecting early-stage cancers. 💰⏳
AI in Immunotherapy Personalization
-
AI-forecasted immunotherapy success based on PD-L1 expression for better outcomes. 🎯🌱
📅 Build your schedule around the topics that interest you.
📥 Download the ELCC 2025_Preview_by_LucidQuest
Contact us for end-to-end conference coverage.